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ABSTRACT
Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes
of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts
or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19
different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment
method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic
cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results
showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was
89.0% in diagnosed cancer patients (ranging from 75.0% to 100.0%). Average number of 11, 5, 8 and 4
CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer,
respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8,
polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage
Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM
expression was more frequently found in most CTCs than vimentin expression, confirming that these
CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression
of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher
numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that
the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to
predict and evaluate therapeutic efficacy as well as to monitoring disease progression.
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Introduction
Circulating tumor cells (CTCs) are derived from primary or
metastatic solid tumors and then enter into the peripheral
blood circulation.1,2 Enumeration of CTCs is one of the key
means of diagnosis in liquid biopsy enabling non-invasive and
periodic monitoring of therapeutic outcomes for cancer
patients in a real-time manner. CTCs are responsible for
tumor metastasis and relapse.3 The clinical significance of
CTCs have been gradually identified in recent years. CTC
diagnosis has been applied to rapidly assess therapeutic
response (e.g. surgery, radiotherapy and chemotherapy as
well as immunotherapy), predict prognosis, monitor thera-
peutic resistance and cancer relapse.4 Detection of CTCs
provides an effective tool for personalized therapy for cancer
patients, offering information for the selection of precision
medicine and holding significance outcomes for clinical
application.
A variety of techniques for the detection of CTCs have
been explored, and the sensitivity and specificity of CTC
detection methods have been determined by the appropriate
CTC enrichment and identification technologies.5 Since CTCs
have critical clinical significance it is necessary to demonstrate
the feasibility and efficiency of this method to predict cancer
progression and prognosis in large cohorts. Therefore, this
study has focused on CTCs detection in order to study the
heterogeneity of detected CTCs within different cancer phe-
notypes and evaluate the application feasibility of subtraction
enrichment method in liquid biopsy.
Materials and methods
Patients and sample collection
A total of 594 peripheral blood samples were collected from
479 patients with various diagnosed and confirmed cancers
and 30 healthy volunteers, from September 2015 to
February 2018. All patients and healthy volunteers that
enrolled in this study have given written consent for parti-
cipation and were approved by the Ethics committees of
Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
All patients’ blood samples, including multiple test samples
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from the same patients were drawn before and after cancer
treatments including surgery, chemotherapy, radiotherapy,
interventional therapy, targeted drug therapy, immunother-
apy and Chinese medicine. The healthy volunteers were
selected with tested HIV, systemic infection, connective
tissue disease, abnormal tumor marker or cancer was
excluded.All experiments were performed within 48 hours
after peripheral blood sample collection and result slides
were collected and stored at 4°C.
Subtraction enrichment of CTCs
Subtraction enrichment experiment was performed according
to the protocol of subtraction enrichment of circulation
tumor cells with immunostaining-fluorescence in situ hybri-
dization (SE-iFISH) (Cytelligen, San Diego, CA, USA).6,7
Briefly, first 2mL of patient peripheral blood was discarded
to avoid epithelial cell contamination and additional 7.5 mL of
blood was collected into a tube containing the Acid Citrate
Dextrose (ACD) anticoagulant solution (Becton Dickinson,
Franklin Lakes, NJ, USA).
According the manufacture’s instruction (Cytelligen, San
Diego, CA, USA) with certain modifications,6,7 the blood
sample was first centrifuged at 200 x g for 15 min, the super-
natant plasma was discarded and the cell pellets were diluted
with 3 ml PBS, mixed thoroughly and layered over 3 mL of
separation matrix,6,7 followed by centrifugation at 450 x g for
6 min at room temperature. The buffy coat solution contain-
ing WBCs and tumor cells but lacking RBCs was collected and
incubated with immuno-magnetic beads, conjugated with a
cocktail of anti-leukocyte monoclonal antibodies, at room
temperature with gentle mixing for 20 min at 125 rpm. The
beads were separated from the mixture using a magnetic
frame. The bead-free solution was then transferred into a
new centrifuge tube, thoroughly washed two times with wash-
ing buffer6,7 at 500xg for 5 min.
Immunostaining and immunofluorescence in suit
hybridization (iFISH)
The cell pellet was subjected to immunostaining with 1 µL
Alexa Fluor 549-conjugated monoclonal anti-CD45, 1 µL
Alexa Fluor 549-conjugated monoclonal anti-CD31 or
1 µL Alexa Fluor 647-conjugated monoclonal anti-CD31,
1µL Alexa Fluor 488-conjugated anti-EpCAM/CK18/PD-L1
and/or 1µL Alexa Fluor 647- conjugated anti-Vimentin. The
mixture was incubated for 20 min in the dark and washed
with washing buffer by centrifuging 950 x g for 4 min to
remove excess antibodies. The cell suspension was then
mixed with 100 µL fixative6,7 and loaded onto Cytelligen
formatted CTC slide. The slide was dried in the air dry oven
at 32°C overnight, followed by hybridization with chromo-
some 8 centromere probe (CEP8) spectrum orange (Vysis,
Abbott Laboratories, Abbott Park IL, USA) for 4 hours
using S500-24 Statspin ThermoBrite Slide Hybridization/
Denaturation System (Abbott Molecular, Des Plaines,
IL, USA).
Characterization of CTCs
FISH hybridization suspension was applied onto slide with
10 µL mounting media (including DAPI). Then the slide was
subjected to the Axio Imager Z2 fluorescence microscope
(Zeiss, Germany) for scanning. Each sample slide was scanned
automatically using Metafer 5 software. This software enables
4-channel fluorescent images of multiple fields covering the
full area of sample for fluorescence detection of cells. 10x
magnification (Zeiss Plan-Apochromat 10x/0.45 M27) was
used to scan the sample slide and exposure times were auto-
selected at 0.04 s for DAPI, 0.44 s for CEP8, 0.8 s for CD45
and fixed at 0.6 s for EpCAM, CK18, PD-L1 and Vimentin.
The captured images were screened manually and CTCs are
identified as CD45−, CD31−, DAPI+, tumor biomarker(s)+/-
with aneuploid chromosome 8. All sample slides were
reviewed by the same investigator.
Statistical analyses
All statistical analyses were performed by IBM SPSS (Version
22.0, www.spss.com) and data were shown as mean ± standard
deviation. In the univariate analysis, significant parameters
were analyzed and P < 0.05 (two-sided) was considered sta-
tistically significant.
Results
Total CTCs detection in the clinical samples of cancer
patients
A total of 594 blood samples, including 126 liver, 85 lung, 39
colorectal, 74 renal, 38 breast, 28 bladder, 45 gastric, 12
esophagus, 12 pancreatic, 14 ovarian and 91 other (gallblad-
der, cervical, prostate, melanoma, endometrial, nasopharyn-
geal, pelvic, glioma, pelvic, cardiac) cancer samples from 479
patients and 30 healthy samples were subjected to subtraction
enrichment, followed by immunofluorescence FISH analysis.
The CTCs were enumerated as non-hematopoietic (CD45
negative), aneuploid chromosome 8 meanwhile excluding
the CECs (CD31 positive) with or without tumor biomarkers
(EpCAM, CK18 and Vimentin) by means of scanning with an
automatic fluorescence microscope. The overall percentage of
CTC positive patients was 89.0%, and detailed information
was summarized as follows (Table 1 & Table S12).
The average number of CTCs detected with negative
enrichment was higher than that with the CellSearch
system
CTCs detections among various carcinomas and detailed clin-
ical information of cancer patients with lung, colorectal, renal,
breast, gastric, bladder, esophagus and other cancers and CTC
subtypes as well as total numbers were described in the
supplementary tables (Table S1-S11), respectively.
For quality control, we collected 30 blood samples from
healthy volunteers, no CTCs were found in this group. Detailed
information was shown in the supplementary table (Table S12).
The overall percentage of positive CTC of liver cancer
patients was 84.9% (107/126) with an average of 5 CTCs/
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7.5 ml and a range of 1–47 CTCs/7.5 ml in peripheral blood.
The overall percentage of CTC positive lung cancer patients
was 92.9% (79/85) with an average of 11 CTCs/7.5 ml and a
range of 1–230 CTCs/7.5 ml in peripheral blood. And the
total positive incidence of CTCs from colorectal cancer
patients was 84.6% (33/39) with an average of 4 CTCs/
7.5 ml and an interval of 1–23 CTCs/7.5 ml in peripheral
blood. The percentage of positive CTC of renal cancer
patients account for 91.9% (68/74) with an average of 8
CTCs/7.5 ml and a range of 1–52 CTCs/7.5 ml in peripheral
blood (Table 1 & Table S12).
In addition, the average numbers of CTCs detected from
lung, liver, renal and colorectal cancer samples in this study
were compared with that of the CellSearch system. The above
results showed that the average numbers of CTCs with our
method were higher than that with the CellSearch system
except in liver cancer (Table S13).
Analysis of triploid, tetraploid and polyploidy of
chromosome 8 on CTCs
One criteria used in this study to characterize CTCs is the
quantification of chromosome aneuploid (Figure 1A). The
CTCs was classified as triploid, tetraploid and polyploid, as
shown in Table 2.
The percentage of positive CTC patients and average num-
bers of triploid, tetraploid and polyploid detected from 10
types of cancer including liver cancer, lung cancer, colorectal
cancer, renal cancer, breast cancer, bladder cancer, gastric
cancer, esophagus cancer, pancreatic cancer, ovarian cancer
and other cancers were shown in Tables 1 and 2, respectively.
There were significant differences between triploidy and tetra-
ploidy (2.1 ± 0.48 & 0.7 ± 0.19, P < 0.05) as well as between
tetraploidy and polyploidy (0.7 ± 0.19 & 2.4 ± 0.55, P < 0.05)
in the patients with stage I and II. The numbers of polyploidy
(2.4 ± 0.55 & 2.6 ± 0.91, P < 0.05) and small CTCs (3.4 ± 0.66
& 3.3 ± 1.17, P < 0.05) between patients with stage I & II and
stage III & IV were compared, respectively, both of which
showed a significant difference (Table 3).
To reveal the properties of CTCs among all 19 types of
cancer in stage I & II and III & IV, triploidy and the number
of small CTCs were compared but showed no significant
difference (P > 0.05). Nevertheless, the number of large
CTCs (1.7 ± 0.32 & 4.8 ± 1.01, P < 0.05), CTM
(0.02 ± 0.025 & 0.3 ± 0.1, P < 0.05), total CTCs (4.5 ± 0.62
& 10.2 ± 1.92, P < 0.05) and the CTCs phenotypes such as
tetraploidy (0.6 ± 0.15 & 1.7 ± 0.30, P < 0.05), polyploidy
(2.0 ± 0.43 & 4.8 ± 1.01, P < 0.05) were significantly different
(Table 4).
Positive expression rates of Vimentin, EpCAM and
Vimentin & EpCAM on CTC positive patients
Among all these 479 patients and 564 blood samples, two
tumor biomarkers were mainly used for CTCs characteriza-
tion, EpCAM and Vimentin. The overall positive rates of
Vimentin (2.4 ± 0.67%) and EpCAM/Vimentin
(24.9 ± 6.08%) among the CTC positive patients were statis-
tically different (P < 0.05, Table 5). Groups with statistically
sufficient cancers were classified and summarized in Table 5.
Analysis of the differences between the groups with more
than 5, 10 and 20 of CTCs
564 blood samples were also divided into several groups accord-
ing to the numbers of CTCs (5, 10, and 20) (Figure 1B). In the
group with more than five CTCs, there were over 30% CTC
positive patients in liver cancer (43/126), lung cancer (33/85),
colorectal cancer (13/39), renal cancer (23/74), bladder cancer
(14/28), esophagus cancer (5/12) and pancreatic cancer (5/12).
The CTC positive patients were below 30% in breast cancer (11/
38), gastric cancer (8/45) and ovarian cancer (4/14).
In the group with more than ten CTCs, the CTC positive
patients were over 20% in bladder cancer (8/28), lung cancer
(22/85) and renal cancer 1 (15/74), while the rates were below
10% in colorectal cancer and breast cancer. Other cancers had
the rates with an interval of 10–20%.
Higher numbers of CTCs were also found in certain can-
cers, e.g., bladder cancer (4/28) and esophagus cancer (2/12),
which accounted for quite a low proportion with a range of 0
to 17% (Figure 1B). There results suggest that the detection of
CTCs in bladder and esophagus cancer would serve as an
available marker for progression and treatment.
Among 19 types of cancers, only the number of CTCs in
liver cancer showed the correlation with cancer stages. 56.5%
of liver cancer patients with more than five CTCs were in
stage Ⅰ and Ⅱ and the other patients were in stage Ⅲ andⅣ. In
the group with more than ten CTCs, 44.4% of patients were in
stage Ⅰ and Ⅱ and the remaining 55.6% were in stage Ⅲ andⅣ,
while none of patients with more than twenty CTCs were in
stage Ⅰ and Ⅱ. Therefore, the high numbers of CTCs indicate
the late stages of cancers.
Table 1. CTC positive rate (CTC number > 0) in different malignancies.
Cancer subtypes Number of patients
Positivity of CTCs (%)
Overall triploid tetraploid polyploid
Liver Cancer 126 107(84.9%) 81 (65.4%) 43 (40.2%) 75(70.1%)
Lung Cancer 85 79 (92.9%) 63 (79.7%) 36 (45.6%) 56 (70.9%)
Colorectal Cancer 39 33 (84.6%) 26 (78.8%) 17 (51.5%) 21 (63.6%)
Renal Cancer 74 68 (91.9%) 48 (70.6%) 28 (41.2%) 51 (75%)
Breast Cancer 38 36 (94.7%) 26 (72.2%) 15 (41.7%) 24 (66.7%)
Bladder Cancer 28 26(92.9%) 20 (76.9%) 15 (57.7%) 16 (61.5%)
Gastric Cancer 45 43 (95.6%) 37 (86.0%) 13 (30.2%) 24 (55.8%)
Esophagus Cancer 12 11 (91.7%) 6 (54.5%) 5 (45.5%) 8 (72.7%)
Ovarian Cancer 14 13 (92.9%) 7 (53.8%) 5 (38.5%) 11 (84.6%)
Pancreatic Cancer 12 11 (91.7%) 10 (90.9%) 10 (90.9%) 5 (45.5%)
Others 91 79 (87.0%) 59 (74.7%) 37 (46.8%) 56 (70.9%)
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Discussions
Detection of CTCs depended on the sensitivity of the enrich-
ment techniques. It has been reported that the overall percen-
tage of CTC positive patients detected with the CellSearch was
71.1%8. In our study, the overall positive rate of CTC detec-
tion was 89.0%. Individual % of CTC positive patients was
varied among cancers with a minimum rate of 75.0%, which is
in consistence with other negative depletion method such as
Figure 1. CTCs distributions among ten prevalent cancers. (A) Images of CTCs with different chromosome 8 ploidies. CTCs nuclei were stained with DAPI (blue) and
the chromosome 8 was illustrated with centromere probe 8 spectrum orange (red dots). (B) The CTC detection numbers are categorized to three groups, as more
than five CTCs, ten CTCs and twenty CTCs in the patients with liver cancer, lung cancer, colorectal cancer, renal cancer, breast cancer, bladder cancer, gastric cancer,
esophagus cancer, pancreatic cancer and ovarian cancer.
Table 2. Number of CTCs in analysis of triploid, tetraploid and polyploidy of
chromosome 8.
Average number of CTC with chromosome 8 polyploidy
Cancer subtypes Triploidy Tetraploidy Polyploidy
Liver cancer 1.7 0.8 2.5
Lung cancer 3.3 1.3 6.1
Colorectal cancer 1.7 0.6 1.6
Renal cancer 1.8 0.7 5.3
Breast cancer 1.6 0.8 2.8
Bladder cancer 4.7 2.0 6.5
Gastric cancer 7.0 0.8 1.0
Esophagus cancer 1.0 1.0 5.3
Pancreatic cancer 2.0 1.6 2.5
Ovarian cancer 1.9 0.9 2.0
Others 2.3 1.0 2.3
Table 3. Statistical analysis of ploidies and sizes of CTC in liver cancer patients
with stage I & II and III & IV.
Stage Statistical analysis
Phenotypes I & II III & IV
Triploidy 2.1 ± 0.48 2.3 ± 0.66 P > 0.05
Tetraploidy 0.7 ± 0.19 1.6 ± 0.58 P > 0.05
Polyploidy 2.4 ± 0.55 2.6 ± 0.91 P < 0.05
Small CTCs 3.4 ± 0.66 3.3 ± 1.17 P < 0.05
Big CTCs 1.8 ± 0.40 2.5 ± 1.00 P > 0.05
Total CTCs 5.3 ± 0.89 6.5 ± 1.51 P > 0.05
Stage I vs II Stage III vs IV
Triploidy & Tetraploidy P < 0.05 P > 0.05
Triploidy & Polyploidy P > 0.05 P > 0.05
Tetraploidy & Polyploidy P < 0.05 P > 0.05
Small CTCs & Big CTCs P > 0.05 P > 0.05
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Cyttel with the positive rates of 84% in lung cancer9 and
68.2% in pancreatic cancer.10 Our method showed signifi-
cantly higher positive incidences of CTCs in lung cancer
(92.9%) and pancreatic cancer (91.7%), liver cancer (84.9%),
colorectal cancer (84.6%), renal cancer (91.9%) and breast
cancer (94.7%), bladder cancer (92.9%), gastric cancer
(95.6%), esophagus cancer (91.7%), pancreatic cancer
(91.7%) and ovarian cancer (92.9%). Based on the comparison
of CellSearch and SE-iFISH in Table S12, the SE-iFISH
method showed relatively higher detection sensitivity of
CTCs than the CellSearch method.
The detection of triploidy, tetraploidy and polyploidy of
chromosome 8 in CTCs in ten types of cancers such as liver,
lung, colorectal, renal, breast, bladder, gastric, esophagus,
pancreatic and ovarian cancers, confirmed the existence of
heterogeneous and dynamic CTCs. Of these ploidies, triploid
and polyploid CTCs were the most prevalent phenotypes,
and tetraploid was frequently shown in lung, colorectal,
pancreatic, bladder and gastric cancers. Among 19 different
carcinomas, tetraploid CTCs, polyploid CTCs, big CTCs,
CTM and total numbers of CTCs in patients with stage Ⅲ
and Ⅳ were statistically higher than patients with stage Ⅰ and
Ⅱ (P < 0.05). In liver cancer, it was also found that the
number of small CTCs in patients with stage Ⅰ and Ⅱ were
statistically higher than patients with stage Ⅲ and Ⅳ
(P < 0.05). In addition, patients in stage Ⅰ and Ⅱ had higher
numbers of triploid CTCs compared with the numbers of
tetraploid CTCs (P < 0.05). Meanwhile, the numbers of
tetraploid CTCs were statistically lower than that of poly-
ploid CTCs (P < 0.05). Furthermore, all the aneuploid CTCs
showed no statistical difference among patients with stage Ⅲ
and Ⅳ. As triploid CTCs and small CTCs were more aggres-
sive (frequently observed), these results may imply that
patients in stage Ⅰ and Ⅱ had higher potential to metastasis
than patients in stage Ⅲ and Ⅳ.
EpCAM and Vimentin were tumor biomarkers of epithelial
and mesenchymal cells, respectively. Interestingly, most CTCs
were found to express EpCAM but not vimentin, confirming
the epithelial phenotype of these CTCs. Additionally, vimen-
tin was primarily distributed in small CTCs and CTM.
Previous studies implied that small CTCs may be closely
related to EMT (Epithelial-mesenchymal transition) and
responsible for cancer metastasis and relapse.11 Considering
the generation of CTCs were mainly the consequence of
EMT,12 the combination of EpCAM and Vimentin had sig-
nificantly higher positive rates than single detection with
Vimentin (P < 0.05). The results strongly indicate that these
two tumor biomarkers could serve as the indicator for tumor
metastasis and relapse.
It had been reported that quantified chromosome ploidy
had various clinical significances, including therapeutic sensi-
tivity, tumor metastasis and relapse.6,7 Therefore, the karyo-
typic characterization of chromosome aneuploid is
particularly important in CTCs.
Studies have shown that aneuploid CTCs was related with
clinical outcomes of gastric cancer patients. More tetraploid
and polyploid CTCs may imply the developed or acquired
chemo-resistance, while triploid CTCs were associated with
the primary chemo-resistance.6,7,13 Our results revealed that
patients with stage Ⅲ andⅣ had more CTCs with tetraploidy.
CTM with two or more CTCs was rarely found but had high
ability to metastasize.14 The decreased expression of EpCAM
on CTCs in breast cancer and colorectal cancer shows the
increase of the potential of tumor growth and metastasis.15-18
Some CTCs were proven to be derived from EMT and
expressed vimentin. Vimentin-positive CTCs have been
thought to be closely related to tumor metastasis and ther-
apeutic resistance.11 Thus, CTCs real-time monitoring as a
non-invasive method could exhibit great potential in evaluat-
ing therapeutic efficacy.11
According to the CTCs statistics from ten types of cancers
(Figure 1B), the patients with more than ten CTCs were very
prevalent. In our data, four cancers have significantly high
amounts of CTCs in peripheral blood, including lung cancer
(25.9%), renal cancer (20.3%), bladder cancer (28.6%), ovarian
cancer (21.4%). These findings suggest that detection of CTCs
may be an available tumor biomarker for immunotherapy or
targeted therapy. One application of CTC test is to monitor
the efficacy of treatment. In our studies, there were 10 patients
with varied cancer types who received a prognostic test. These
patients had pre done CTC tests before and after specific
therapeutics such as radiotherapy, chemotherapy, surgery,
Chinese medicine, immunotherapy, targeted therapy, cell
therapy and microwave therapy, and five patients with differ-
ent cancer types received ongoing monitoring ranging from
6 months to 2 years. CTC numbers among all five patients
have shown a dramatic change during cancer treatment and a
deceased trend ultimately. These results support the use of
CTCs to monitor treatment efficacy. The CTC numbers
decreased in 5 patients by this test. However, the other 5
patients showed an increased CTC numbers and continued
follow-up monitoring.
In summary, this study revealed that higher numbers of
CTCs, tetraploid, polyploid and large CTCs are associated
with patients with stage Ⅲ and Ⅳ. CTCs enumeration can
be utilized as a biomarker for evaluation of therapeutic effect.
Likewise, the quantification of chromosome aneuploid
Table 4. Statistical analysis of ploidies and sizes of CTC in all 19 cancers with
stage I & II and III & IV.
Stage Statistical analysis
Phenotypes I & II III & IV
Triploidy 1.8 ± 0.31 3.4 ± 1.02 P > 0.05
Tetraploidy 0.6 ± 0.15 1.7 ± 0.30 P < 0.05
Polyploidy 2.0 ± 0.43 4.8 ± 1.04 P < 0.05
Small CTCs 2.7 ± 0.46 5.1 ± 1.24 P > 0.05
Big CTCs 1.7 ± 0.32 4.8 ± 1.01 P < 0.05
CTM 0.02 ± 0.025 0.3 ± 0.10 P < 0.05
Total CTCs 4.5 ± 0.62 10.2 ± 1.92 P < 0.05
Table 5. Positive Expression rates of Vimentin, EpCAM and Vimentin/EpCAM on
CTCs in liver cancer and all cancers.
EpCAM+ Vimentin+ EpCAM/Vimentin+
Liver
cancer
8.1 ± 2.41% 4.8 ± 2.68% 51.4 ± 14.52%
All cancer 6.1 ± 1.37% 2.4 ± 0.67% 24.9 ± 6.08%
All cancer EpCAM+ &
Vimentin+
EpCAM+ & EpCAM/
Vimentin+
Vimentin+ & EpCAM/
Vimentin+
Statistical
analysis
P > 0.05 P > 0.05 P < 0.05
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performed by iFISH for CTCs may be shown to be supportive
as a predictive biomarker in monitoring disease progression.
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